All In Biotech

Drug Trial Radar · NCT04812535

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Open Label, Multicenter Phase II Study of the C5a Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients With PD-1 or PD-L1 Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)

Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

30

Actual

Start

Mar 31, 2021

Primary completion

Jun 4, 2024

Study completion Jun 4, 2024

Sponsor

Lead sponsor
InflaRx GmbHIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Mar 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, "non comparative", non-randomized, Phase II study. Patients will be enrolled in 2 treatment arms

Conditions

  • SCC - Squamous Cell Carcinoma of Skin

Interventions

  • VilobelimabDrug

    Vilobelimab Monotherapy

  • Vilobelimab + pembrolizumab combination therapyDrug

    Vilobelimab + pembrolizumab combination therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Overall Response Rate (Best ORR) - Arm A and Arm BTime frame: Up to 36 months
  2. Dose-limiting Toxicity (DLT) - Arm BTime frame: Cycle 1 Day 1 - Cycle 1 Day 36

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Anschutz Cancer Pavilion

    Aurora, Colorado

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Orlando Health, Inc.

    Orlando, Florida

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida

  • Inova Schar Cancer Institute

    Fairfax, Virginia

  • University Hospital Antwerp (UZA)

    Edegem, Belgium

  • St. Augustinus Hospital

    Wilrijk, Belgium

  • University Hospital Center of Grenoble Alpes, Department of Dermatology

    Grenoble, France

  • South Lyon Hospital Center

    Lyon, France

  • CHU APHM la Timone / Aix Marseille University, Dermatology and Skin Cancer Department

    Marseille, France

  • St. Louis Hospital

    Paris, France

  • University Hospital Center of Poitiers, Department of Oncology

    Poitiers, France

  • University Hospital Erlangen, Department of Dermatology

    Erlangen, Germany

  • University Duisburg-Essen, University Hospital Essen, Department of Dermatology

    Essen, Germany

  • Frankfurt University Clinic, Department of Dermatology, Venereology and Allergology

    Frankfurt, Germany

  • University Hospital Hamburg-Eppendorf

    Hamburg, Germany

  • University Hospital Leipzig, Department of Dermatology, Venereology and Allergology

    Leipzig, Germany

  • University Hospital Regensburg, Clinic and Policlinic for Dermatology

    Regensburg, Germany

  • University Hospital Tuebingen, Department of Dermatology

    Tübingen, Germany

  • University Hospital Vall d'Hebron

    Barcelona, Spain

  • ICO Hospitalet

    Barcelona, Spain

  • MD Anderson International Cancer Center Spain

    Madrid, Spain

  • Regional University Hospital of Malaga

    Málaga, Spain

  • University Clinical Hospital of Salamanca

    Salamanca, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.